...Newton Biocapital. DeuterOncology has a sublicense to worldwide rights outside greater China for all the compounds Octimet Oncology N.V....

...firm and will invest alongside Takke and Willem Broekaert. Margetson is CEO of cancer company Octimet Oncology N.V....

...a plethora of c-MET inhibitors in the clinic for cancer and two on the market, Octimet Oncology N.V....
...Novartis declined to comment, and AZ did not respond to request for comment. COMPANY PROFILE Octimet Oncology N.V....
...NYSE:JNJ), New Brunswick, N.J. Merck KGaA (Xetra:MRK), Darmstadt, Germany Novartis AG (NYSE:NVS; SIX:NOVN), Basel, Switzerland Octimet Oncology N.V....

...cell gene therapy Gene/Cell therapy; Hematology; Endocrine/ Metabolic Phase I/II V-Bio Venture Fund I (2015) Octimet Oncology N.V....

...S.A. , as well as cancer companies iTeos Therapeutics S.A. , eTheRNA immunotherapies N.V. and Octimet Oncology N.V. Virginia...

...Investors in Octimet Oncology N.V. ’s series A round believe the selectivity of OMO-1 for its target, plus...

...On Jan. 19, cancer play Octimet Oncology N.V. (Beerse, Belgium) raised €11.3 million ($12 million) in a series...
...Ventures and Fund+. Droia Oncology Ventures and Omnes Capital also participated. Octimet Oncology N.V. , Beerse, Belgium Alicia Parker Octimet Oncology...

...Cancer play Octimet Oncology N.V. (Beerse, Belgium) raised EUR 11.3 million ($12 million) in a series A financing...
...J&J's scientific, technical and business capabilities (see BioCentury Extra, March 16, 2016) . Becky Simon Johnson & Johnson Octimet Oncology...

...will join the incubator, along with immuno-oncology company eTheRNA N.V. (Brussels, Belgium) and cancer play Octimet Oncology...